12:00 AM
 | 
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taxus Liberte: Additional data

Additional data from the ATLAS trial in 871 patients showed that Taxus Liberte and Taxus Express led to similar rates of target lesion revascularization (TLR) at 5 years (11% vs. 11.5%, p=0.72). Rates of...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >